🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to researchers.

A Global Challenge

Gonorrhoea infections are increasing worldwide, with figures suggesting over 82 million new cases each year. Especially elevated rates are observed in Africa and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the context of growing infection rates, escalating drug resistance and the extremely scarce treatment choices currently available.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". A tracking program found that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Secure Approval

Zoliflodacin, alternatively called a brand name, was approved by the US Food and Drug Administration in December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Scientists believe that focused deployment of this new drug will help delay the development of resistance.

Another new antibiotic, created by the pharmaceutical company GSK, gained clearance in the same week. This medication, which is employed against urinary tract infections, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This milestone signifies a significant shift in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Research Study Outcomes and Worldwide Availability

Based on results released by a major medical journal, the new drug cured the vast majority of genital gonorrhoea infections. This establishes an comparable level with the existing first-line therapy, which uses an injection and a pill. The study involved nearly 1,000 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the rights to make available and distribute the drug in a wide range of developing nations.

Medical professionals directly involved have expressed optimism. Having a one-pill regimen like this is described as a "critical tool" for gonorrhoea control. This is viewed as vital to alleviate the strain of the disease for individuals and to prevent the spread of highly drug-resistant gonorrhoea around the world.